Achieve Life Sciences (NASDAQ:ACHV – Get Rating)‘s stock had its “outperform” rating reissued by equities research analysts at Oppenheimer in a research report issued on Friday, Benzinga reports. They currently have a $17.00 price target on the biopharmaceutical company’s stock. Oppenheimer’s price objective would indicate a potential upside of 290.80% from the stock’s current price.
Achieve Life Sciences Price Performance
Shares of ACHV stock opened at $4.35 on Friday. The stock has a 50 day moving average price of $4.83 and a 200 day moving average price of $3.62. Achieve Life Sciences has a 52-week low of $2.00 and a 52-week high of $8.13. The company has a debt-to-equity ratio of 15.10, a quick ratio of 3.03 and a current ratio of 3.03. The firm has a market capitalization of $77.87 million, a P/E ratio of -1.09 and a beta of 1.44.
Achieve Life Sciences (NASDAQ:ACHV – Get Rating) last released its earnings results on Thursday, March 16th. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.07. During the same period in the prior year, the company earned ($0.76) EPS. As a group, sell-side analysts predict that Achieve Life Sciences will post -2.13 earnings per share for the current year.
Institutional Trading of Achieve Life Sciences
Large investors have recently modified their holdings of the company. Prelude Capital Management LLC purchased a new stake in shares of Achieve Life Sciences in the 2nd quarter worth approximately $49,000. Charles Schwab Investment Management Inc. purchased a new stake in Achieve Life Sciences during the first quarter worth $79,000. HRT Financial LP bought a new stake in Achieve Life Sciences during the 4th quarter valued at $32,000. Raymond James & Associates bought a new stake in Achieve Life Sciences during the 1st quarter valued at $99,000. Finally, Morgan Stanley raised its position in shares of Achieve Life Sciences by 437.4% in the 4th quarter. Morgan Stanley now owns 13,547 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 11,026 shares in the last quarter. Hedge funds and other institutional investors own 21.11% of the company’s stock.
Achieve Life Sciences Company Profile
Achieve Life Sciences, Inc is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.
Receive News & Ratings for Achieve Life Sciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Achieve Life Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.